Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Min Hwan Kim

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Communications Biology|April 10, 2021
Genomic landscape of extraordinary responses in metastatic breast cancerSun Min Lim, Eunyoung Kim, Kyung Hae Jung, et al.
British Journal of Cancer|June 24, 2020
Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade responseMin Hwan Kim, Jae-Hwan Kim, Ji Min Lee, et al.
Scientific Reports|June 19, 2023
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancerKyoungmin Lee, Jongwon Lee, Jungmin Choi, et al.
Cancer Science|July 9, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancerHiroji Iwata, Binghe Xu, Sung-Bae Kim, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancerChanghee Park, Koung Jin Suh, Se Hyun Kim, et al.
Journal of the National Cancer Institute|May 11, 2023
Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancerMin Hwan Kim, Gun Min Kim, Jin Mo Ahn, et al.
Genome Biology|April 14, 2026
Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancerDong Ki Lee, Min Hwan Kim, Yumi Hwang, et al.
Clinical and Molecular Hepatology|December 28, 2025
Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancerDaeseong Kim, Nam Suk Sim, Seonjeong Woo, et al.
EMBO Molecular Medicine|October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancerMi Ran Yun, Hun Mi Choi, You Won Lee, et al.
The New England Journal of Medicine|March 23, 2022
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast CancerJavier Cortés, Sung-Bae Kim, Wei-Pang Chung, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Communications Biology|April 10, 2021
Genomic landscape of extraordinary responses in metastatic breast cancerSun Min Lim, Eunyoung Kim, Kyung Hae Jung, et al.
British Journal of Cancer|June 24, 2020
Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade responseMin Hwan Kim, Jae-Hwan Kim, Ji Min Lee, et al.
Scientific Reports|June 19, 2023
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancerKyoungmin Lee, Jongwon Lee, Jungmin Choi, et al.
Cancer Science|July 9, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancerHiroji Iwata, Binghe Xu, Sung-Bae Kim, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancerChanghee Park, Koung Jin Suh, Se Hyun Kim, et al.
Journal of the National Cancer Institute|May 11, 2023
Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancerMin Hwan Kim, Gun Min Kim, Jin Mo Ahn, et al.
Genome Biology|April 14, 2026
Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancerDong Ki Lee, Min Hwan Kim, Yumi Hwang, et al.
Clinical and Molecular Hepatology|December 28, 2025
Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancerDaeseong Kim, Nam Suk Sim, Seonjeong Woo, et al.
EMBO Molecular Medicine|October 22, 2019
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancerMi Ran Yun, Hun Mi Choi, You Won Lee, et al.
The New England Journal of Medicine|March 23, 2022
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast CancerJavier Cortés, Sung-Bae Kim, Wei-Pang Chung, et al.
Pageof 12